2025 Q3 -tulosraportti
125 päivää sitten
‧56 min
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 17.4.2025 | ||
2024 Q3 -tulosraportti 6.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 t sittenI just bought in again at 4,60 and found this as a possible reason for the drop :Horizon represents a fundamental reorganization of our operating model and cost structure. We are simplifying our cost base, reallocating resources to higher-value, intellectual property-driven programs, and improving operational leverage across the company to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial Framework and Mid-Term Outlook Given the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec’s two business segments. Preliminary Results for Fiscal Year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on 8. april 2026. Discovery & Preclinical Development (&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-on-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-on-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon’s Financial Impact and 2026 Expectations Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euro from the structural Horizon measures by the end of 2027, of which a positive contribution will already be realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euro in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euro realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-Term Framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to below 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on 8. april 2026.- ·5.11.2025 · MuokattuDoes anyone have info about today's fall, is it the financial report that is so bad?·5 t sittenI have just bought in again at 4,60 and found this as a possible reason for the fall: Horizon represents a fundamental reorganization of our operating model and cost structure. We simplify our cost base, reallocate resources to higher-value, intellectual property-driven programs, and improve operational leverage across the business to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial framework and mid-term outlook Considering the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec's two business segments. Preliminary results for fiscal year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited financial figures for the full year 2025, subject to the completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on April 8, 2026. Discovery & Preclinical Development (D&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-over-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-over-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon's financial impact and expectations for 2026 Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euros from the structural Horizon measures by the end of 2027, of which a positive contribution will already have been realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euros in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euros realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-term framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to less than 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on April 8, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
125 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenI just bought in again at 4,60 and found this as a possible reason for the drop :Horizon represents a fundamental reorganization of our operating model and cost structure. We are simplifying our cost base, reallocating resources to higher-value, intellectual property-driven programs, and improving operational leverage across the company to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial Framework and Mid-Term Outlook Given the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec’s two business segments. Preliminary Results for Fiscal Year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on 8. april 2026. Discovery & Preclinical Development (&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-on-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-on-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon’s Financial Impact and 2026 Expectations Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euro from the structural Horizon measures by the end of 2027, of which a positive contribution will already be realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euro in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euro realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-Term Framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to below 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on 8. april 2026.
- ·5.11.2025 · MuokattuDoes anyone have info about today's fall, is it the financial report that is so bad?·5 t sittenI have just bought in again at 4,60 and found this as a possible reason for the fall: Horizon represents a fundamental reorganization of our operating model and cost structure. We simplify our cost base, reallocate resources to higher-value, intellectual property-driven programs, and improve operational leverage across the business to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial framework and mid-term outlook Considering the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec's two business segments. Preliminary results for fiscal year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited financial figures for the full year 2025, subject to the completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on April 8, 2026. Discovery & Preclinical Development (D&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-over-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-over-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon's financial impact and expectations for 2026 Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euros from the structural Horizon measures by the end of 2027, of which a positive contribution will already have been realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euros in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euros realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-term framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to less than 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on April 8, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 17.4.2025 | ||
2024 Q3 -tulosraportti 6.11.2024 |
2025 Q3 -tulosraportti
125 päivää sitten
‧56 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 8.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 13.8.2025 | ||
2025 Q1 -tulosraportti 6.5.2025 | ||
2024 Q4 -tulosraportti 17.4.2025 | ||
2024 Q3 -tulosraportti 6.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 t sittenI just bought in again at 4,60 and found this as a possible reason for the drop :Horizon represents a fundamental reorganization of our operating model and cost structure. We are simplifying our cost base, reallocating resources to higher-value, intellectual property-driven programs, and improving operational leverage across the company to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial Framework and Mid-Term Outlook Given the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec’s two business segments. Preliminary Results for Fiscal Year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited full-year 2025 financial figures, subject to completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on 8. april 2026. Discovery & Preclinical Development (&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-on-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-on-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon’s Financial Impact and 2026 Expectations Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euro from the structural Horizon measures by the end of 2027, of which a positive contribution will already be realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euro in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euro realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-Term Framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to below 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on 8. april 2026.
- ·5.11.2025 · MuokattuDoes anyone have info about today's fall, is it the financial report that is so bad?·5 t sittenI have just bought in again at 4,60 and found this as a possible reason for the fall: Horizon represents a fundamental reorganization of our operating model and cost structure. We simplify our cost base, reallocate resources to higher-value, intellectual property-driven programs, and improve operational leverage across the business to create value for our stakeholders. Although 2026 will be a transition year, our goal is a structurally more focused organization with improved long-term profitability and strengthened cash flow generation through 2027 and beyond.” Financial framework and mid-term outlook Considering the start of Horizon and the expected transition year in 2026, Evotec is revising its mid-term financial framework to reflect a phased development from 2026 to 2030. The revised framework incorporates the timing of restructuring measures and the continued evolution of the revenue mix across Evotec's two business segments. Preliminary results for fiscal year 2025 (unaudited) To provide transparency as part of the updated framework, Evotec is sharing preliminary, unaudited financial figures for the full year 2025, subject to the completion of year-end closing and audit procedures. For the full year 2025, Evotec expects results to fall within the previously communicated guidance ranges: Group revenue of approx. €788 million at the upper end of the guidance of €760-800 million (€811 million at constant exchange rates (CER)) Adjusted Group EBITDA of approx. €41 million versus guidance of €30-50 million (€52 million CER) Evotec will report the final results for the fourth quarter and full year 2025 on April 8, 2026. Discovery & Preclinical Development (D&PD) Preliminary, unaudited revenues for the D&PD segment are expected to amount to approx. €529 million (€540 million CER), representing a decrease of 13 % year-over-year. Adjusted EBITDA for the segment is expected to amount to approx. -€12 million (-€5 million CER). Just – Evotec Biologics (JEB) Preliminary, unaudited revenues for the JEB segment are expected to amount to approx. €259 million (€271 million CER), representing an increase of 40 % year-over-year. Adjusted EBITDA contribution from JEB is expected to amount to approx. €53 million (€57 million CER). Horizon's financial impact and expectations for 2026 Horizon is essentially expected to be completed by the end of 2027. 2026 will represent a transition year, with significant operational improvements expected to become increasingly visible in the second half of the year. Evotec expects total cost savings of approx. 75 million euros from the structural Horizon measures by the end of 2027, of which a positive contribution will already have been realized in 2026. To implement Horizon, Evotec expects total cash restructuring costs of approx. 100 million euros in the period 2026-2028. Non-cash components related to asset impairments are also expected. Evotec enters 2026 with annual savings of approx. 60 million euros realized in 2025, fully integrated into the structurally lower operating costs and driven by improved capital discipline and a gradually more technology-driven revenue mix and base. These structural cost reductions, combined with improved utilization and a shift towards higher-margin, technology and platform-based activities, are expected to improve operational leverage and support sustained margin expansion from 2027 onwards. For the full year 2026, Evotec expects: Group revenue of approx. €700-780 million (€730-810 million CER) Adjusted Group EBITDA of approx. €0-40 million (€10-50 million CER) Mid-term framework 2026-2030 Evotec is preparing a new mid-term framework for 2026-2030 to account for the timing and impact of Horizon, while maintaining its growth ambition. The framework trajectory reflects a phased path. Group revenue is expected to grow to > €1 billion (8-12 % CAGR) Adjusted EBITDA margin is expected to reach 20 % by 2028 and exceed this level by 2030 The framework trajectory reflects: Expected recovery of the early drug discovery and development market Cost reductions from Horizon with positive contributions from 2026 Continued shift towards higher-margin, technology-based, capital-efficient revenue streams Continued CAPEX-light approach to less than 10 % of Revenue Operational leverage as growth resumes after the transition year 2026 This phased approach defines a clear path from operational reset, through transition, to sustainable margin expansion and scalable growth by 2030. Further details on the mid-term framework will be provided in the final reporting for the fourth quarter and full year 2025 on April 8, 2026.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt